Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agentsM J Millan, M Brocco, J M Rivet, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidolM J Millan, A Gobert, A Newman-Tancredi, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194V Audinot, A Newman-Tancredi, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1992
S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptorsM J Millan, J M Rivet, H Canton, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and racloprideM J Millan, A Newman-Tancredi, M Brocco, et al.
Synapse (New York, N.Y.)|December 28, 1999
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive statesM J Millan, A Newman-Tancredi, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidolM J Millan, R Schreiber, A Dekeyne, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 18, 2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterizationM J Millan, D Cussac, G Milligan, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profileM J Millan, A Gobert, A Newman-Tancredi, et al.
Pageof 6